Using the reference central Cobas tissue test results of the FLAURA trial, positive percent agreements with the Cobas plasma test results for EGFR Del19 and L858R detection were 79 and 68%, respectively, supporting the utility of Cobas tissue and plasma testing to aid the selection of patients with EGFR mutated advanced NSCLC for first-line osimertinib treatment [188]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.